C. de Mendoza, Graham Taylor, A. Gessain, Andrea K. Thoma-Kress, Charles R. M. Bangham, Jan Vesterbacka, Roberto Accolla, Ali Bazarbachi, Jan van Weyenbergh, Lucy Cook, Jorge Casseb, Juan Carlos Ramos, Carolina Rosadas, Beatrice Macchi, O. Cassar, V. Soriano
{"title":"HTLV-1感染的病毒学、发病机制、流行病学和临床管理。第 30 届 HTLV 欧洲研究网络（HERN 2023）会议记录","authors":"C. de Mendoza, Graham Taylor, A. Gessain, Andrea K. Thoma-Kress, Charles R. M. Bangham, Jan Vesterbacka, Roberto Accolla, Ali Bazarbachi, Jan van Weyenbergh, Lucy Cook, Jorge Casseb, Juan Carlos Ramos, Carolina Rosadas, Beatrice Macchi, O. Cassar, V. Soriano","doi":"10.1515/nipt-2023-0025","DOIUrl":null,"url":null,"abstract":"Abstract The 30th workshop of the HTLV European Research Network (HERN) was held in Madrid on September 15–16, 2023. Over fifty researchers from Europe and America convened for a two-day conference to update and discuss basic science, epidemiology, clinical management and therapeutics for patients with HTLV-1 infection. Scientific topics addressed included new estimates for HTLV-1 in Europe; impact of antenatal screening on mother-to-child HTLV-1 infections; new insights into the molecular epidemiology of HTLV-1; reports of elite controllers for HTLV-1 infection; role of antiretrovirals as HTLV-1 pre-exposure prophylaxis; and prospects for a HTLV-1 vaccine. The group agreed to submit a formal request to WHO for increasing the global surveillance and awareness of HTLV-1. This viral infection is a potentially life-threatening, neglected condition with neither treatment nor vaccine. At this time, expanding HTLV-1 screening is the most effective way to reduce viral dissemination.","PeriodicalId":74278,"journal":{"name":"NeuroImmune pharmacology and therapeutics","volume":"3 2","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Virology, pathogenesis, epidemiology and clinical management of HTLV-1 infection. Proceedings of the 30th HTLV European research network (HERN 2023)\",\"authors\":\"C. de Mendoza, Graham Taylor, A. Gessain, Andrea K. Thoma-Kress, Charles R. M. Bangham, Jan Vesterbacka, Roberto Accolla, Ali Bazarbachi, Jan van Weyenbergh, Lucy Cook, Jorge Casseb, Juan Carlos Ramos, Carolina Rosadas, Beatrice Macchi, O. Cassar, V. Soriano\",\"doi\":\"10.1515/nipt-2023-0025\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract The 30th workshop of the HTLV European Research Network (HERN) was held in Madrid on September 15–16, 2023. Over fifty researchers from Europe and America convened for a two-day conference to update and discuss basic science, epidemiology, clinical management and therapeutics for patients with HTLV-1 infection. Scientific topics addressed included new estimates for HTLV-1 in Europe; impact of antenatal screening on mother-to-child HTLV-1 infections; new insights into the molecular epidemiology of HTLV-1; reports of elite controllers for HTLV-1 infection; role of antiretrovirals as HTLV-1 pre-exposure prophylaxis; and prospects for a HTLV-1 vaccine. The group agreed to submit a formal request to WHO for increasing the global surveillance and awareness of HTLV-1. This viral infection is a potentially life-threatening, neglected condition with neither treatment nor vaccine. At this time, expanding HTLV-1 screening is the most effective way to reduce viral dissemination.\",\"PeriodicalId\":74278,\"journal\":{\"name\":\"NeuroImmune pharmacology and therapeutics\",\"volume\":\"3 2\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-01-11\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"NeuroImmune pharmacology and therapeutics\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1515/nipt-2023-0025\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"NeuroImmune pharmacology and therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/nipt-2023-0025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Virology, pathogenesis, epidemiology and clinical management of HTLV-1 infection. Proceedings of the 30th HTLV European research network (HERN 2023)
Abstract The 30th workshop of the HTLV European Research Network (HERN) was held in Madrid on September 15–16, 2023. Over fifty researchers from Europe and America convened for a two-day conference to update and discuss basic science, epidemiology, clinical management and therapeutics for patients with HTLV-1 infection. Scientific topics addressed included new estimates for HTLV-1 in Europe; impact of antenatal screening on mother-to-child HTLV-1 infections; new insights into the molecular epidemiology of HTLV-1; reports of elite controllers for HTLV-1 infection; role of antiretrovirals as HTLV-1 pre-exposure prophylaxis; and prospects for a HTLV-1 vaccine. The group agreed to submit a formal request to WHO for increasing the global surveillance and awareness of HTLV-1. This viral infection is a potentially life-threatening, neglected condition with neither treatment nor vaccine. At this time, expanding HTLV-1 screening is the most effective way to reduce viral dissemination.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
